CLR 131

DRUG3 trials

Sponsors

Cellectar Biosciences, Inc., University of Wisconsin, Madison

Conditions

DIPGEwing SarcomaHead and Neck CancerHigh-Grade GliomaNeuroblastomaOsteosarcomaPediatric Brain TumorPediatric Lymphoma

Phase 1

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

Active, not recruitingNCT03478462

Cellectar Biosciences, Inc.DIPG, Ewing Sarcoma, Neuroblastoma +5

Start: 2019-04-30End: 2027-02-25Target: 30Updated: 2026-03-18

CLR 131 Combined With Radiation for Head and Neck Cancer

CompletedNCT04105543

University of Wisconsin, MadisonHead and Neck Cancer

Start: 2019-12-20End: 2024-02-01Updated: 2025-09-02

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

Active, not recruitingNCT05610891

Cellectar Biosciences, Inc.High-Grade Glioma

Start: 2023-10-01End: 2026-09-01Target: 50Updated: 2026-03-18

Related Papers

Abstract A019: Precision radiotherapy for incurable brain tumors: Phase 1b dose & regimen optimization study of iopofosine I 131 in inoperable relapsed or refractory pediatric high-grade glioma, interim data assessment

Cancer Research2025-09-25

Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion study.

2024-12-12

CTNI-77. PHASE 1 DOSE FINDING STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF IOPOFOSINE I 131 IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH INOPERABLE RELAPSED OR REFRACTORY HIGH-GRADE GLIOMAS: A TRIAL-IN-PROGRESS

Neuro-Oncology2024-11-01

EPCT-09. CLR 131 IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC MALIGNANCIES

Neuro-Oncology2020-12-011 citations